<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               2 DOSAGE AND ADMINISTRATION<BR>               <BR>               <BR>                  <BR>                     <BR>                        Recommended Dosing Regimen (2)<BR>                         <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" border="single" width="728.000" ID="id_65174931-a27a-4d52-a714-8e73f4630cb1"><BR>                           <col width="26.1%"/><BR>                           <col width="28.2%"/><BR>                           <col width="23.5%"/><BR>                           <col width="22.3%"/><BR>                           <tbody><BR>                              <tr ID="id_5a5700c6-a808-4a31-9a0c-914d64fe2b60"><BR>                                 <td align="center" valign="top" styleCode="Botrule Toprule Rrule Lrule"><BR>                                    <content styleCode="bold">Infection</content><BR>                                 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"><BR>                                    <content styleCode="bold">Loading Dose</content><BR>                                 </td><BR>                                 <td align="center" valign="top" colspan="2" styleCode="Botrule Rrule"><BR>                                    <content styleCode="bold">Maintenance Dose</content><BR>                                    <footnote ID="id-03323e46-71e6-4ee5-b2d8-b8e68993c75e">Increase dose when voriconazole is coadministered with phenytoin or efavirenz (<linkHtml href="#i4i_interactions_id_e1b2c433-39d0-4d7d-b867-c6b8d1c9b24f">7</linkHtml>); Decrease dose in patients with hepatic impairment (<linkHtml href="#i4i_section_id_f33fa2d3-ba83-47a5-a397-6ce731940a4d">2.7</linkHtml>)</footnote><BR>                                    <footnote ID="id-c4ab7c77-e554-4ee5-a6ab-e937f35d858d">Oral and intravenous maintenance doses do not produce the same voriconazole exposures. A 200 mg oral dose provides an exposure similar to a 3 mg/kg IV dose; 300 mg oral dose provides an exposure similar to a 4 mg/kg IV dose.</footnote><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_89697f82-db23-47b0-b66b-3176fa133757"><BR>                                 <td align="left" valign="top" styleCode="Lrule Botrule Rrule"/><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"><BR>                                    <content styleCode="bold">IV</content><BR>                                 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"><BR>                                    <content styleCode="bold">IV</content><BR>                                 </td><BR>                                 <td align="center" valign="top" styleCode="Botrule Rrule"><BR>                                    <content styleCode="bold">Oral<footnote ID="id-b6c675be-82d9-48e4-845a-fb412871ed4c">Adult patients who weigh less than 40 kg should receive half of the oral maintenance dose.</footnote><BR>                                    </content><BR>                                 </td><BR>                              </tr><BR>                              <tr ID="id_47a3b921-ef6d-4a46-9dd6-edfddbd6c3b8"><BR>                                 <td align="center" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Invasive Aspergillosis<footnote ID="id-213f4888-56b4-4a51-af02-d8b238af95c8">In a clinical study, the median duration of IV voriconazole therapy was 10 days; the median duration of oral voriconazole therapy was 76 days.</footnote><BR>                                    </content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">6 mg/kg q12h for the first 24 hours</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">4 mg/kg q12h</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">200 mg q12h</td><BR>                              </tr><BR>                              <tr ID="id_5523e301-5692-44ec-8597-a77e8c2620ea"><BR>                                 <td align="center" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Candidemia in nonneutropenics and other deep tissue <content styleCode="italics">Candida</content> infections</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">6 mg/kg q12h for the first 24 hours</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">3 to 4 mg/kg q12h<footnote ID="id-0a0afccb-4f92-4662-a800-5dd5efb0bd67">Patients with candidemia received 3 mg/kg q12h; patients with other deep tissue <content styleCode="italics">Candida </content>infections received 4 mg/kg.</footnote><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">200 mg q12h</td><BR>                              </tr><BR>                              <tr ID="id_19815b8d-6651-4e9c-9587-d50d4b3c9026"><BR>                                 <td align="center" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Esophageal Candidiasis</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">not evaluated</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">not evaluated</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">200 mg q12h</td><BR>                              </tr><BR>                              <tr ID="id_c7cfdb53-6923-406b-b5cf-cc87ec88796b"><BR>                                 <td align="center" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                    <content styleCode="bold">Scedosporiosis and Fusariosis</content><BR>                                 </td><BR>                                 <td align="left" valign="top" styleCode="Rrule">6 mg/kg q12h for the first 24 hours</td><BR>                                 <td align="left" valign="top" styleCode="Rrule">4 mg/kg q12h</td><BR>                                 <td align="left" valign="top" styleCode="Botrule Rrule">200 mg q12h</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR> <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.1 Instructions for Use in All Patients<BR>                     <BR>                        Voriconazole tablets should be taken at least one hour before or after a meal.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.3 Recommended Dosing in Adults<BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           Invasive aspergillosis and serious fungal infections due to Fusarium spp. and Scedosporium apiospermum<BR>                           <BR>                              See Table 1. Therapy must be initiated with the specified loading dose regimen of intravenous voriconazole on Day 1 followed by the recommended maintenance dose regimen. Intravenous treatment should be continued for at least 7 days. Once the patient has clinically improved and can tolerate medication given by mouth, the oral tablet form or oral suspension form of voriconazole may be utilized. The recommended oral maintenance dose of 200 mg achieves a voriconazole exposure similar to 3 mg/kg IV; a 300 mg oral dose achieves an exposure similar to 4 mg/kg IV. Switching between the intravenous and oral formulations is appropriate because of the high bioavailability of the oral formulation in adults [see Clinical Pharmacology (12)<BR>                                 ]. <BR>                           <BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           Candidemia in nonneutropenic patients and other deep tissue Candida infections<BR>                           <BR>                              See Table 1. Patients should be treated for at least 14 days following resolution of symptoms or following last positive culture, whichever is longer.<BR>                           <BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           Esophageal Candidiasis<BR>                           <BR>                              See Table 1. Patients should be treated for a minimum of 14 days and for at least 7 days following resolution of symptoms.<BR>                              <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" border="single" width="727.000" ID="id_32f0634e-4448-419f-a45d-61dc31b5868f"><BR>                                 <caption ID="id_3adc8777-d9d6-4d51-8e9f-0a1232f0daba">Table 1. Recommended Dosing Regimen</caption><BR>                                 <col width="30.8%"/><BR>                                 <col width="29.3%"/><BR>                                 <col width="19.9%"/><BR>                                 <col width="19.9%"/><BR>                                 <tbody><BR>                                    <tr ID="id_ceca7d2a-24c9-460b-ae77-36c69f0f90bd"><BR>                                       <td align="center" valign="middle" styleCode="Botrule Toprule Rrule Lrule"><BR>                                          <content styleCode="bold">Infection </content><BR>                                       </td><BR>                                       <td align="center" valign="middle" styleCode="Botrule Rrule"><BR>                                          <content styleCode="bold">Loading dose </content><BR>                                       </td><BR>                                       <td align="center" valign="middle" colspan="2" styleCode="Botrule Rrule"><BR>                                          <content styleCode="bold">Maintenance Dose<footnote ID="id-b18f0138-4543-4aa8-b886-b2b36a0c1892">Increase dose when voriconazole is coadministered with phenytoin or efavirenz (<linkHtml href="#i4i_interactions_id_e1b2c433-39d0-4d7d-b867-c6b8d1c9b24f">7</linkHtml>); Decrease dose in patients with hepatic impairment (<linkHtml href="#i4i_section_id_f33fa2d3-ba83-47a5-a397-6ce731940a4d">2.7</linkHtml>)</footnote><BR>                                             <footnote ID="id-103ab772-a24e-4f5a-bbfb-ca878abe842d">In healthy volunteer studies, the 200 mg oral q12h dose provided an exposure (AUC<sub>&#964;</sub>) similar to a 3 mg/kg IV q12h dose; the 300 mg oral q12h dose provided an exposure (AUC<sub>&#964;</sub>) similar to a 4 mg/kg IV q12h dose [<content styleCode="italics">see <linkHtml href="#i4i_clinical_pharmacology_id_57c86c55-df7a-467a-a40d-7df76ad927a2">Clinical Pharmacology (12)</linkHtml><BR>                                                </content>]</footnote><BR>                                          </content><BR>                                       </td><BR>                                    </tr><BR>                                    <tr ID="id_ab571468-5638-47ea-8d21-be6af73374c7"><BR>                                       <td align="left" valign="top" styleCode="Lrule Botrule Rrule"/><BR>                                       <td align="center" valign="middle" styleCode="Botrule Rrule"><BR>                                          <content styleCode="bold">IV </content><BR>                                       </td><BR>                                       <td align="center" valign="middle" styleCode="Botrule Rrule"><BR>                                          <content styleCode="bold">IV </content><BR>                                       </td><BR>                                       <td align="center" valign="middle" styleCode="Botrule Rrule"><BR>                                          <content styleCode="bold">Oral<footnote ID="id-db5ce59b-b4a3-486e-a2cb-9e8925f8432b">Adult patients who weigh less than 40 kg should receive half of the oral maintenance dose.</footnote><BR>                                          </content><BR>                                       </td><BR>                                    </tr><BR>                                    <tr ID="id_2c588ceb-ca24-46d9-a1cb-b2f04746d65d"><BR>                                       <td align="left" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                          <content styleCode="bold">Invasive Aspergillosis<footnote ID="id-085aac61-40d4-431a-b0e6-212017eadf34">In a clinical study of invasive aspergillosis, the median duration of IV voriconazole therapy was 10 days (range 2 to 90 days). The median duration of oral voriconazole therapy was 76 days (range 2 to 232 days) [<content styleCode="italics">see <linkHtml href="#i4i_section_id_14d0d4d0-648f-4fb7-9b01-0e7373389d48">Clinical Studies (14.1)</linkHtml><BR>                                                </content>]</footnote><BR>                                          </content><BR>                                       </td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">6 mg/kg q12h for the first 24 hours </td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">4 mg/kg q12h </td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">200 mg q12h </td><BR>                                    </tr><BR>                                    <tr ID="id_b200ca8a-ae54-481c-807b-babe9fa36d54"><BR>                                       <td align="center" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                          <content styleCode="bold">Candidemia in non-neutropenic patients and other deep tissue <content styleCode="italics">Candida </content>infections </content><BR>                                       </td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">6 mg/kg q12h for the first 24 hours </td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">3 to 4 mg/kg q12h<footnote ID="id-11028fd0-d77c-4fb3-b7b1-2b0a2d55ec92">In clinical trials, patients with candidemia received 3 mg/kg IV q12h as primary therapy, while patients with other deep tissue <content styleCode="italics">Candida </content>infections received 4 mg/kg q12h as salvage therapy. Appropriate dose should be based on the severity and nature of the infection.</footnote><BR>                                       </td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">200 mg q12h </td><BR>                                    </tr><BR>                                    <tr ID="id_9689d279-c9b5-483b-9c0e-ea3faf7c505a"><BR>                                       <td align="left" valign="middle" styleCode="Lrule Botrule Rrule"><BR>                                          <content styleCode="bold">Esophageal Candidiasis </content><BR>                                       </td><BR>                                       <td align="center" valign="middle" styleCode="Botrule Rrule"><BR>                                          <footnote ID="id-64a12e8d-2425-48bb-b1f8-802d1e4b0e48">Not evaluated in patients with esophageal candidiasis.</footnote><BR>                                       </td><BR>                                       <td align="center" valign="middle" styleCode="Botrule Rrule"><BR>                                          <footnoteRef IDREF="id-64a12e8d-2425-48bb-b1f8-802d1e4b0e48"/><BR>                                       </td><BR>                                       <td align="center" valign="middle" styleCode="Botrule Rrule">200 mg q12h </td><BR>                                    </tr><BR>                                    <tr ID="id_2bb44eed-b464-46f4-99dc-033b35bee34f"><BR>                                       <td align="center" valign="top" styleCode="Lrule Botrule Rrule"><BR>                                          <paragraph><BR>                                             <content styleCode="bold">Scedosporiosis and </content><BR>                                          </paragraph><BR>                                          <content styleCode="bold">Fusariosis </content><BR>                                       </td><BR>                                       <td align="justify" valign="top" styleCode="Rrule"><BR>                                          <paragraph>6 mg/kg q12h for the first 24 hours</paragraph><BR>                                       </td><BR>                                       <td align="center" valign="top" styleCode="Rrule">4 mg/kg q12h </td><BR>                                       <td align="center" valign="top" styleCode="Botrule Rrule">200 mg q12h </td><BR>                                    </tr><BR>                                 </tbody><BR>                              </table><BR>                              <BR><BR><BR> <BR>                           <BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.4 Dosage Adjustment<BR>                     <BR>                        If patient response is inadequate, the oral maintenance dose may be increased from 200 mg every 12 hours (similar to 3 mg/kg IV q12h) to 300 mg every 12 hours (similar to 4 mg/kg IV q12h). For adult patients weighing less than 40 kg, the oral maintenance dose may be increased from 100 mg every 12 hours to 150 mg every 12 hours. If patient is unable to tolerate 300 mg orally every 12 hours, reduce the oral maintenance dose by 50 mg steps to a minimum of 200 mg every 12 hours (or to 100 mg every 12 hours for adult patients weighing less than 40 kg).<BR>                        If patient is unable to tolerate 4 mg/kg IV q12h, reduce the intravenous maintenance dose to 3 mg/kg q12h.<BR>                        The maintenance dose of voriconazole should be increased when coadministered with phenytoin or efavirenz [see Drug Interactions (7)<BR>                           ].<BR>                        The maintenance dose of voriconazole should be reduced in patients with mild to moderate hepatic impairment, Child-Pugh Class A and B [see Dosage and Administration (2.7)<BR>                           ]. There are no PK data to allow for dosage adjustment recommendations in patients with severe hepatic impairment (Child-Pugh Class C). Duration of therapy should be based on the severity of the patient’s underlying disease, recovery from immunosuppression and clinical response.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.7 Use in Patients with Hepatic Impairment<BR>                     <BR>                        In the clinical program, patients were included who had baseline liver function tests (ALT, AST) up to 5 times the upper limit of normal. No dose adjustment is necessary in patients with this degree of abnormal liver function, but continued monitoring of liver function tests for further elevations is recommended [see Warnings and Precautions (5.9)<BR>                           ].<BR>                        It is recommended that the standard loading dose regimens be used but that the maintenance dose be halved in patients with mild to moderate hepatic cirrhosis (Child-Pugh Class A and B) [see Clinical Pharmacology (12.3)<BR>                           ].<BR>                        Voriconazole tablets have not been studied in patients with severe hepatic cirrhosis (Child-Pugh Class C) or in patients with chronic hepatitis B or chronic hepatitis C disease. Voriconazole tablets have been associated with elevations in liver function tests and clinical signs of liver damage, such as jaundice and should only be used in patients with severe hepatic impairment if the benefit outweighs the potential risk. Patients with hepatic insufficiency must be carefully monitored for drug toxicity.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.8 Use in Patients with Renal Impairment<BR>                     <BR>                        The pharmacokinetics of orally administered voriconazole are not significantly affected by renal impairment. Therefore, no adjustment is necessary for oral dosing in patients with mild to severe renal impairment [see Clinical Pharmacology (12.3)<BR>                           ].<BR>                        In patients with moderate or severe renal impairment (creatinine clearance < 50 mL/min), accumulation of the intravenous vehicle, SBECD, occurs. Oral voriconazole should be administered to these patients, unless an assessment of the benefit/risk to the patient justifies the use of intravenous voriconazole. Serum creatinine levels should be closely monitored in these patients, and, if increases occur, consideration should be given to changing to oral voriconazole therapy [see Warnings and Precautions (5.10)<BR>                           ].<BR>                        Voriconazole is hemodialyzed with clearance of 121 mL/min. The intravenous vehicle, SBECD, is hemodialyzed with clearance of 55 mL/min. A 4-hour hemodialysis session does not remove a sufficient amount of voriconazole to warrant dose adjustment.<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>